Recent technical crossovers in FOXO’s RSI levels point toward a neutral zone. The forecast short-term remains range-bound while awaiting catalyst events from the company’s R&D pipeline. Foxo Technologies applies artificial intelligence and machine learning to better understand the epigenetic biomarkers underlying human health. If applicable, all outstanding convertible preferred stock and debt, stock options, warrants, and equity incentive plans will be proportionately affected. The exercise prices and the number of shares issuable upon exercise, of the outstanding stock options and warrants, and the number of shares available for future issuance under the equity incentive plans, will be adjusted in accordance with their respective terms. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder’s ownership percentage of the Company’s shares with the exception of those holders of fractional shares. FOXO’s latest regulatory filings highlight efforts to expand longevity research IP. Industry analysts note that announcements in this niche often trigger speculative rallies, making the FOXO stock forecast sensitive to news flows.